ProQR Therapeutics NV is a biopharmaceutical company founded in 2012 and engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders. ProQR Therapeutics’ Axiomer® technology enables the body to repair its own RNA specifically and reversibly. The company’s Antisense oligonucleotides (AONs) are designed to inhibit the expression of a target RNA, or adjust the splicing pattern of an RNA, in this way repairing the RNA and thereby allowing a functional protein to be produced. Initially the company focused on cystic fibrosis, but it eventually expanded to other diseases that can potentially be targeted using this proprietary platform technology.